Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention : A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis

• Published in: Journal of the American College of Cardiology Vol. 51; no. 21; pp. 2028 - 2033
• Main Authors: ANTMAN, Elliott M, WIVIOTT, Stephen D, MURPHY, Sabina A, VOITK, Juri, HASIN, Yonathan, WIDIMSKY, Petr, CHANDNA, Harish, MACIAS, William, MCCABE, Carolyn H, BRAUNWALD, Eugene
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Science 27.05.2008; Elsevier Limited
• Subjects: Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - therapy; Acute coronary syndromes; Angina, Unstable - drug therapy; Angina, Unstable - therapy; Angioplasty, Balloon, Coronary; Aspirin - therapeutic use; Biological and medical sciences; Blood platelets; Cardiology; Cardiology. Vascular system; Combined Modality Therapy; Coronary heart disease; Diseases of the cardiovascular system; Drug therapy; Drug Therapy, Combination; Heart; Heart attacks; Hemorrhage - chemically induced; Humans; Kaplan-Meier Estimate; Medical sciences; Myocardial Infarction - drug therapy; Myocardial Infarction - therapy; Myocardial Ischemia - prevention & control; Myocarditis. Cardiomyopathies; Patients; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - therapeutic use; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Population; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Stents; Survival analysis; Thiophenes - administration & dosage; Thiophenes - adverse effects; Thiophenes - therapeutic use; Thrombosis; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use; Human; Myocardial infarction; Late; Prognosis; Angioplasty; Coronary artery; Instrumentation therapy; Cardiovascular disease; Coronary heart disease; Myocardial disease; Fibrinolysis; Optimization; Prasugrel; Improvement; Platelet; Analysis; Evolution; Early; Circulatory system; Inhibition; Cardiology; Acute coronary syndrome

We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Prasugrel is superior to clop...